In a significant development for Alzheimer’s treatment, Anavex
Life Sciences has announced positive results from a recent analysis of its investigational oral
therapy, Anavex 2-73 (blarcamesine). The data, derived from a Phase 2b/3
clinical trial, indicate that the drug significantly slows both cognitive
decline and neurodegeneration in individuals with early-stage Alzheimer’s disease. 

The trial enrolled 509 participants aged 60 to 85, who were either experiencing mild cognitive
impairments or mild dementia due to Alzheimer’s. Over a 48-week period,
participants were randomly assigned to receive either one of two doses of
Anavex 2-73 or a placebo. The primary objectives were to assess the therapy’s
effects on cognition and overall daily functioning. 

Anavex Life Sciences reported that patients treated with Anavex 2-73 had an 84% higher likelihood of experiencing meaningful
cognitive improvements compared to those on a placebo. Additionally, the
therapy was associated with a 45% slower rate of cognitive decline, as measured
by the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog). 

Further analysis revealed significant benefits in brain health. Patients on Anavex 2-73
exhibited a marked reduction in brain volume loss, a key indicator of
neurodegeneration. Blood tests also showed a favorable shift in amyloid-beta
protein ratios, a biomarker closely linked to Alzheimer’s progression. 

The safety profile of Anavex 2-73 was another highlight. The treatment was
generally well tolerated, with dizziness being the most common side effect,
typically mild to moderate in severity. 

Marwan Noel Sabbagh, MD, a professor of neurology and advisor to Anavex Life Sciences,
emphasized the potential of Anavex 2-73 as a convenient, orally administered
treatment that offers both cognitive and neuroprotective benefits. 

As Anavex Life Sciences prepares for discussions with regulatory authorities across the globe,
the positive trial results position Anavex 2-73 as a promising candidate in the
fight against Alzheimer’s disease. Refer to this article to learn more. 

Learn more about Anavex on https://www.cnbc.com/quotes/AVXL